Ptc Therapeutics (PTCT) Operating Expenses (2012 - 2026)

Ptc Therapeutics' Operating Expenses history runs 15 years deep, the most recent figure standing at $227.6 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 10.55% year-over-year to $227.6 million in Q1 2026; TTM through Mar 2026 was $885.4 million, a 16.44% decrease from a year earlier, with the FY2025 full-year figure at $863.7 million, down 22.14% from the prior year.
• Operating Expenses declined to $227.6 million in Q1 2026 per PTCT's latest filing, from $236.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $423.4 million in Q2 2023 and bottomed at $205.9 million in Q1 2025.
• The 5-year median for Operating Expenses is $255.6 million (2024), against an average of $277.9 million.
• Across the five-year window, Operating Expenses jumped 64.16% in 2023 and slumped 46.4% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $367.8 million in 2022, then slipped by 18.09% to $301.2 million in 2023, then grew by 24.67% to $375.6 million in 2024, then sank by 37.15% to $236.0 million in 2025, then retreated by 3.57% to $227.6 million in 2026.
• Per Business Quant, the three latest PTCT Operating Expenses figures stand at $227.6 million (Q1 2026), $236.0 million (Q4 2025), and $208.0 million (Q3 2025).